MEDICAMEQPharmaceuticals
Medicamen Biotech Ltd — Profit & Loss Statement
₹223.30
-4.88%
Medicamen Biotech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.12 Cr | -0.12 Cr | — |
| Tax Rate For Calcs | 0.34 | 0.27 | 0.14 | 0.18 | — |
| Normalized EBITDA | 20.11 Cr | 24.57 Cr | 27.23 Cr | 25.94 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.90 Cr | -0.68 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.90 Cr | -0.68 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 7.11 Cr | 10.93 Cr | 14.84 Cr | 14.90 Cr | — |
| Reconciled Depreciation | 7.08 Cr | 7.09 Cr | 6.37 Cr | 5.77 Cr | — |
| Reconciled Cost Of Revenue | 84.62 Cr | 92.60 Cr | 85.99 Cr | 67.46 Cr | — |
| EBITDA | 20.11 Cr | 24.57 Cr | 26.33 Cr | 25.27 Cr | — |
| EBIT | 13.04 Cr | 17.47 Cr | 19.97 Cr | 19.50 Cr | — |
| Net Interest Income | -3.16 Cr | -4.40 Cr | -2.67 Cr | -1.81 Cr | — |
| Interest Expense | 3.16 Cr | 4.40 Cr | 2.92 Cr | 1.40 Cr | — |
| Normalized Income | 7.11 Cr | 10.93 Cr | 15.62 Cr | 15.45 Cr | — |
| Net Income From Continuing And Discontinued Operation | 7.11 Cr | 10.93 Cr | 14.84 Cr | 14.90 Cr | — |
| Total Expenses | 155.75 Cr | 164.16 Cr | 121.98 Cr | 96.45 Cr | — |
| Diluted Average Shares | 1.38 Cr | 1.46 Cr | 1.27 Cr | 1.22 Cr | — |
| Basic Average Shares | 1.38 Cr | 1.46 Cr | 1.27 Cr | 1.22 Cr | — |
| Diluted EPS | 5.16 | 7.50 | 11.73 | 12.19 | — |
| Basic EPS | 5.16 | 7.50 | 11.73 | 12.19 | — |
| Diluted NI Availto Com Stockholders | 7.11 Cr | 10.93 Cr | 14.84 Cr | 14.90 Cr | — |
| Net Income Common Stockholders | 7.11 Cr | 10.93 Cr | 14.84 Cr | 14.90 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 7.11 Cr | 10.93 Cr | 14.84 Cr | 14.90 Cr | — |
| Minority Interests | 0.55 Cr | 1.44 Cr | 0.12 Cr | 0.00 | — |
| Net Income Including Noncontrolling Interests | 6.56 Cr | 9.49 Cr | 14.73 Cr | 14.90 Cr | — |
| Net Income Continuous Operations | 6.56 Cr | 9.49 Cr | 14.73 Cr | 14.90 Cr | — |
| Tax Provision | 3.32 Cr | 3.58 Cr | 2.32 Cr | 3.20 Cr | — |
| Pretax Income | 9.88 Cr | 13.08 Cr | 17.05 Cr | 18.09 Cr | — |
| Other Non Operating Income Expenses | 6.24 Cr | 2.33 Cr | 0.25 Cr | 0.13 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.90 Cr | -0.68 Cr | — |
| Net Non Operating Interest Income Expense | -3.16 Cr | -4.40 Cr | -2.67 Cr | -1.81 Cr | — |
| Interest Expense Non Operating | 3.16 Cr | 4.40 Cr | 2.92 Cr | 1.40 Cr | — |
| Operating Income | 6.79 Cr | 15.15 Cr | 18.89 Cr | 19.00 Cr | — |
| Operating Expense | 71.14 Cr | 71.56 Cr | 35.99 Cr | 28.99 Cr | — |
| Other Operating Expenses | 32.20 Cr | 34.40 Cr | 0.30 Cr | 0.46 Cr | — |
| Depreciation And Amortization In Income Statement | 7.07 Cr | 7.09 Cr | 6.37 Cr | 5.77 Cr | — |
| Depreciation Income Statement | 7.07 Cr | 7.09 Cr | 6.26 Cr | 5.67 Cr | — |
| Gross Profit | 77.93 Cr | 86.71 Cr | 54.88 Cr | 47.99 Cr | — |
| Cost Of Revenue | 84.62 Cr | 92.60 Cr | 85.99 Cr | 67.46 Cr | — |
| Total Revenue | 162.55 Cr | 179.31 Cr | 140.87 Cr | 115.45 Cr | — |
| Operating Revenue | 162.55 Cr | 179.31 Cr | 140.87 Cr | 115.45 Cr | — |
| Interest Income | — | 0.72 Cr | 0.72 Cr | 0.14 Cr | 0.15 Cr |
| Other Special Charges | — | -0.07 Cr | -99000.00 | -60000.00 | -27285.00 |
| Interest Income Non Operating | — | 0.72 Cr | 0.72 Cr | 0.14 Cr | 0.15 Cr |
| Amortization | — | 0.17 Cr | 0.11 Cr | 0.10 Cr | 0.06 Cr |
| Rent Expense Supplemental | — | — | 0.40 Cr | 0.25 Cr | 0.22 Cr |
| Write Off | — | — | 0.91 Cr | 0.68 Cr | 0.00 |
| Total Other Finance Cost | — | — | 0.47 Cr | 0.54 Cr | 0.45 Cr |
| Selling General And Administration | — | — | 8.27 Cr | 7.72 Cr | 4.15 Cr |
| Selling And Marketing Expense | — | — | 3.89 Cr | 3.24 Cr | 1.61 Cr |
| General And Administrative Expense | — | — | 4.38 Cr | 4.48 Cr | 2.54 Cr |
| Rent And Landing Fees | — | — | 0.40 Cr | 0.25 Cr | 0.22 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Medicamen Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.